Investment Partners’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $451K | Sell |
16,073
-1,276
| -7% | -$34K | 0.16% | 113 |
|
|
2025
Q4 | $432K | Sell |
17,349
-771
| -4% | -$19.4K | 0.15% | 109 |
|
|
2025
Q3 | $462K | Buy |
18,120
+203
| +1% | +$5.01K | 0.16% | 109 |
|
|
2025
Q2 | $434K | Sell |
17,917
-1,713
| -9% | -$39.9K | 0.16% | 109 |
|
|
2025
Q1 | $497K | Sell |
19,630
-986
| -5% | -$25.8K | 0.21% | 98 |
|
|
2024
Q4 | $547K | Buy |
20,616
+1,647
| +9% | +$44.7K | 0.23% | 89 |
|
|
2024
Q3 | $549K | Sell |
18,969
-499
| -3% | -$14.6K | 0.23% | 86 |
|
|
2024
Q2 | $545K | Sell |
19,468
-1,127
| -5% | -$31K | 0.24% | 87 |
|
|
2024
Q1 | $572K | Sell |
20,595
-1,411
| -6% | -$39.2K | 0.26% | 85 |
|
|
2023
Q4 | $634K | Sell |
22,006
-6,635
| -23% | -$201K | 0.31% | 83 |
|
|
2023
Q3 | $950K | Sell |
28,641
-4,203
| -13% | -$149K | 0.5% | 54 |
|
|
2023
Q2 | $1.2M | Sell |
32,844
-193
| -0.6% | -$7.51K | 0.63% | 46 |
|
|
2023
Q1 | $1.35M | Buy |
33,037
+135
| +0.4% | +$5.83K | 0.71% | 41 |
|
|
2022
Q4 | $1.69M | Sell |
32,902
-36,737
| -53% | -$1.76M | 0.89% | 31 |
|
|
2022
Q3 | $3.05M | Buy |
69,639
+37,644
| +118% | +$1.83M | 0.91% | 24 |
|
|
2022
Q2 | $1.68M | Buy |
31,995
+218
| +0.7% | +$11.1K | 0.82% | 33 |
|
|
2022
Q1 | $1.65M | Buy |
31,777
+6,042
| +23% | +$313K | 0.7% | 34 |
|
|
2021
Q4 | $1.52M | Buy |
25,735
+56
| +0.2% | +$2.77K | 0.62% | 38 |
|
|
2021
Q3 | $1.1M | Buy |
25,679
+120
| +0.5% | +$5.32K | 0.5% | 46 |
|
|
2021
Q2 | $1M | Buy |
25,559
+1,314
| +5% | +$51.1K | 0.46% | 49 |
|
|
2021
Q1 | $878K | Buy |
24,245
+1,273
| +6% | +$45.2K | 0.43% | 56 |
|
|
2020
Q4 | $846K | Sell |
22,972
-1,153
| -5% | -$42.3K | 0.45% | 56 |
|
|
2020
Q3 | $840K | Sell |
24,125
-7,809
| -24% | -$274K | 0.5% | 50 |
|
|
2020
Q2 | $991K | Sell |
31,934
-10,627
| -25% | -$361K | 0.58% | 51 |
|
|
2020
Q1 | $1.32M | Buy |
42,561
+1,509
| +4% | +$51.4K | 0.95% | 34 |
|
|
2019
Q4 | $1.53M | Sell |
41,052
-253
| -0.6% | -$9.01K | 1.03% | 34 |
|
|
2019
Q3 | $1.41M | Buy |
41,305
+6,518
| +19% | +$237K | 1.03% | 33 |
|
|
2019
Q2 | $1.43M | Sell |
34,787
-1,193
| -3% | -$47.4K | 1.03% | 34 |
|
|
2019
Q1 | $1.45M | Buy |
35,980
+958
| +3% | +$38.4K | 1.05% | 33 |
|
|
2018
Q4 | $1.45M | Buy |
35,022
+569
| +2% | +$23.6K | 1.22% | 24 |
|
|
2018
Q3 | $790 | Buy |
34,453
+1,841
| +6% | +$70.9K | 0.44% | 46 |
|
|
2018
Q2 | $1.12M | Sell |
32,612
-2,293
| -7% | -$78.4K | 0.83% | 35 |
|
|
2018
Q1 | $1.18M | Sell |
34,905
-703
| -2% | -$24.2K | 0.88% | 35 |
|
|
2017
Q4 | $1.22M | Buy |
35,608
+1,974
| +6% | +$67.3K | 0.91% | 35 |
|
|
2017
Q3 | $1.14M | Sell |
33,634
-9,200
| -21% | -$296K | 0.98% | 35 |
|
|
2017
Q2 | $1.36M | Buy |
42,834
+155
| +0.4% | +$4.89K | 1.24% | 28 |
|
|
2017
Q1 | $1.39M | Sell |
42,679
-1,895
| -4% | -$59.7K | 1.33% | 24 |
|
|
2016
Q4 | $1.37M | Sell |
44,574
-36,435
| -45% | -$1.11M | 1.34% | 24 |
|
|
2016
Q3 | $2.6M | Buy |
81,009
+50,146
| +162% | +$1.68M | 1.47% | 19 |
|
|
2016
Q2 | $1.03M | Sell |
30,863
-33,174
| -52% | -$1.06M | 1.03% | 36 |
|
|
2016
Q1 | $1.96M | Buy |
64,037
+34,188
| +115% | +$977K | 1.28% | 23 |
|
|
2015
Q4 | $908K | Sell |
29,849
-622
| -2% | -$19.6K | 1.09% | 36 |
|
|
2015
Q3 | $909K | Sell |
30,471
-1,665
| -5% | -$53.4K | 1.19% | 34 |
|
|
2015
Q2 | $1.02M | Buy |
32,136
+43
| +0.1% | +$1.4K | 1.23% | 28 |
|
|
2015
Q1 | $1.06M | Buy |
32,093
+169
| +0.5% | +$5.37K | 1.16% | 24 |
|
|
2014
Q4 | $947K | Buy |
+31,924
| New | +$915K | 1.09% | 30 |
|
Other funds holding PFE
VCM
VPM
Investment Partners's PFE Position: Q1 2026 in Review
Investment Partners reduced its Pfizer (PFE) stake by 7.4% in Q1 2026, selling an estimated $34K and leaving 16,073 shares worth $451K. The position accounts for 0.16% of the portfolio, ranked #113.
Investment Partners first reported a position in PFE in Q4 2014 and has held it in 46 quarters since. The position peaked at $3.05M in Q3 2022. 2,938 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- Investment Partners held 16,073 shares of Pfizer worth $451K as of Q1 2026.
- Investment Partners sold 1,276 Pfizer shares in Q1 2026, an estimated $34K.
- Pfizer made up 0.16% of Investment Partners's portfolio in Q1 2026, its #113 holding.
- Investment Partners first reported a position in Pfizer in Q4 2014 and has held it in 46 quarters since.
- Investment Partners's Pfizer position peaked at $3.05M in Q3 2022.
- 2,938 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on Investment Partners's 13F filing for Q1 2026, filed 5 May 2026.